Bionano Genomics (BNGO) Cash & Current Investments (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Cash & Current Investments data on file, last reported at $13.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 24.9% year-over-year to $13.7 million; the trailing twelve-month figure through Mar 2026 stood at $13.7 million (down 24.9% YoY), and the FY2025 full-year result was $13.3 million, down 34.12% from the prior year.
• Cash & Current Investments improved to $13.7 million in Q1 2026, from $13.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $216.5 million in Q1 2022 to a low of $5.1 million in Q4 2022.
• A 5-year average of $62.2 million and a median of $21.6 million in 2025 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments plunged 97.97% in 2022 and surged 1211.55% in 2023, its largest moves.
• Tracing BNGO's Cash & Current Investments over 5 years: stood at $5.1 million in 2022, then surged by 1211.55% to $66.8 million in 2023, then tumbled by 69.79% to $20.2 million in 2024, then slumped by 34.12% to $13.3 million in 2025, then rose by 3.02% to $13.7 million in 2026.
• Business Quant data shows BNGO's Cash & Current Investments at $13.7 million in Q1 2026, $13.3 million in Q4 2025, and $21.6 million in Q3 2025.